The news sent shares in Moderna soaring 145% to $154, while Merck’s stock was up more than 12% to $152.

The drug, called “intismeran autogene,” is based on the same messenger RNA (mRNA) technology behind COVID-19 vaccines.

Researchers have for years been trying to apply mRNA treatments against cancer, but this was the first time such a drug showed positive results in a large, late-stage clinical trial.

“Today marks an extraordinary milestone for Moderna, for mRNA science and, most importantly, for patients with cancer,” Moderna CEO Stephane Bancel said in a statement.

The trial lasted about a year and involved 1,137 patients who, following surgical removal of their cancers, were randomized into groups, with two-thirds receiving the new treatment plus pembrolizumab—the current standard-of-care drug—while the rest received pembrolizumab alone.